Sponsors (2)
Introduced September 10, 2025 by Buddy Carter · Last progress September 10, 2025
The bill strengthens transparency, program integrity, and patient point-of-sale affordability for low-income and uninsured populations, but does so by imposing substantial new reporting, compliance, and penalty regimes that could raise provider costs, privacy risks, and—if enforcement is aggressive—reduce access to 340B-supported care.
Taxpayers, policymakers, researchers, and the public gain far greater transparency and oversight because the bill requires centralized, site-level reporting, published audit standards, and searchable data on 340B margins, contracts, and grant/subgrantee information.
Low-income, uninsured, and other vulnerable patients face lower out-of-pocket costs and more predictable drug affordability because the bill mandates point-of-sale reductions, sliding fee scales ($0/$35/$50 caps), and extends discount obligations to contract pharmacies.
State Medicaid programs, Medicare contractors, and taxpayers are better protected from duplicate discounts and overpayments because the bill standardizes billing methodologies, requires timely data to exclude 340B‑purchased units from rebate calculations, and creates HHS audit authority to prevent improper manufacturer rebate claims.
Hospitals, clinics, contract pharmacies, and related providers face large new administrative, IT, and reporting burdens because the bill requires site-level, claim-level, patient-level, and grant/subgrantee reporting on tight timelines.
Safety‑net hospitals and the patients they serve risk reduced access to discounted drugs and services because aggressive audits, retroactive repayments, per‑claim penalties, deregistration, and large civil monetary penalties could strain or remove providers from 340B participation.
Patients and covered entities face privacy and competitive risks because the bill requires collection and sharing of detailed, claim- and entity-identified financial data that could enable re‑identification or reveal commercially sensitive information.
Based on analysis of 38 sections of legislative text.
Strengthens 340B eligibility, reporting, audits, contract-pharmacy limits, claim modifiers, and patient cost caps; creates a claims clearinghouse and expands enforcement.
Requires major new transparency, audit, and compliance rules for the 340B drug discount program: hospitals and other covered entities must submit detailed, site-level cost and claims data to HHS, allow audits, limit and register contract pharmacies and child sites, and adopt patient affordability protections for low-income patients. Creates a federally run claims clearinghouse and new civil monetary penalties for noncompliance, directs HHS rulemaking and audits, and preempts most state or local laws that conflict with the federal 340B rules. The law strengthens eligibility standards for certain nonprofit hospitals that rely on government contracts to serve uninsured patients, tightens rules for nonhospital covered entities and subgrantees, mandates claim-level modifiers and rapid electronic reporting, and imposes payment and contract limits on third‑party administrators and contract pharmacies. It also bans discrimination by insurers and PBMs against 340B entities and requires HHS to publish much of the reported data publicly.